Obesity and cardiovascular disease: friend or foe?

被引:137
|
作者
Kim, Seong Hwan [1 ]
Despres, Jean-Pierre [2 ]
Koh, Kwang Kon [3 ,4 ]
机构
[1] Korea Univ, Div Cardiol, Ansan Hosp, Ansan, South Korea
[2] Univ Laval, Fac Med, Quebec Heart & Lung Inst, Dept Kinesiol, Laval, PQ, Canada
[3] Gachon Univ, Div Cardiol, Dept Cardiovasc Med, Ctr Heart,Gil Med Ctr, 774 Beongil 21, Incheon 405760, South Korea
[4] Gachon Cardiovasc Res Inst, Incheon, South Korea
关键词
Obesity; Metabolically healthy obesity; Obesity paradox; Cardiovascular disease; Cardiometabolic syndrome; BODY-MASS INDEX; METABOLICALLY-HEALTHY OBESITY; CORONARY-HEART-DISEASE; PERIVASCULAR ADIPOSE-TISSUE; ALL-CAUSE MORTALITY; LEFT-VENTRICULAR STRUCTURE; IN-HOSPITAL OUTCOMES; CARDIORESPIRATORY FITNESS; MYOCARDIAL-INFARCTION; RISK-FACTORS;
D O I
10.1093/eurheartj/ehv509
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity is currently one of the greatest public health issues worldwide. However, despite its known deleterious effects on the cardiovascular system and its association with numerous cardiovascular diseases (CVD), recent findings leading to the development of concepts such as metabolically healthy obesity, the obesity paradox, and protective subcutaneous fat depots have raised a lively debate on the disparate effects of obesity on health outcomes. Regarding the concept of metabolically healthy obesity, by presumably labelling a subset of obese people as metabolically healthy, physicians may not feel pressed to curb the current obesity epidemic and prevent the next generation of people from becoming obese. Another issue is that the most commonly used anthropometric index to define obesity, the body mass index, is at the core of the controversy because of its limitations including its inability to discriminate between fat mass and muscle mass. Many recent epidemiological and metabolic studies have used other indices such as waist-hip ratio, waist circumference, and imaging (computed tomography or magnetic resonance imaging) measurements of visceral adiposity and of ectopic fat depots. In addition, emerging evidence supports the importance of cardiorespiratory fitness, skeletal muscle mass and strength in patients with obesity as useful variables to predict CVD risk beyond adiposity. In this review, we will discuss the complex and disparate effects of obesity on CVD, particularly focusing on whether, under given circumstances, it could be harmful, potentially harmless or neutral, or even possibly protective.
引用
收藏
页码:3560 / 3568B
页数:11
相关论文
共 50 条
  • [1] The Effects of Dexamethasone on Cardiovascular Disease: Friend or Foe?
    Qian-Feng Han
    Jia-Hui Liu
    De-Gang Mo
    [J]. Cardiovascular Drugs and Therapy, 2023, 37 : 847 - 848
  • [2] Loop diuretics in cardiovascular disease: friend or foe?
    Rosengren, Annika
    [J]. EUROPEAN HEART JOURNAL, 2024,
  • [3] The Effects of Dexamethasone on Cardiovascular Disease: Friend or Foe?
    Han, Qian-Feng
    Liu, Jia-Hui
    Mo, De-Gang
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (05) : 847 - 848
  • [4] The Effect of Hypoxia on Cardiovascular Disease: Friend or Foe?
    Savla, Jainy J.
    Levine, Benjamin D.
    Sadek, Hesham A.
    [J]. HIGH ALTITUDE MEDICINE & BIOLOGY, 2018, 19 (02) : 124 - 130
  • [5] Oral anticoagulant treatment:: friend or foe in cardiovascular disease?
    Schurgers, LJ
    Aebert, H
    Vermeer, C
    Bültmann, B
    Janzen, J
    [J]. BLOOD, 2004, 104 (10) : 3231 - 3232
  • [6] Alcohol: a cardiovascular friend or foe?
    Di Castelnuovo, Augusto
    de Gaetano, Giovanni
    [J]. MINERVA CARDIOLOGY AND ANGIOLOGY, 2024,
  • [7] Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease
    Ait-Aissa, Karima
    Ebben, Johnathan D.
    Kadlec, Andrew O.
    Beyer, Andreas M.
    [J]. PHARMACOLOGICAL RESEARCH, 2016, 111 : 422 - 433
  • [8] The Wnt/frizzled pathway in cardiovascular development and disease: Friend or foe?
    van de Schans, Veerle A. M.
    Smits, Jos F. M.
    Blankesteijn, W. Matthijs
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 585 (2-3) : 338 - 345
  • [9] S-glutathionylation, friend or foe in cardiovascular health and disease
    Rashdan, N. A.
    Shrestha, B.
    Pattillo, C. B.
    [J]. REDOX BIOLOGY, 2020, 37
  • [10] Phosphoinositide 3-kinase: friend and foe in cardiovascular disease
    Ghigo, Alessandra
    Li, Mingchuan
    [J]. FRONTIERS IN PHARMACOLOGY, 2015, 6